Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
Figure 3
Postprandial proinsulin/insulin ratio in patients treated with sulfonylurea, insulin Glargine, or DPP-IV inhibitors compared to nondiabetic healthy controls (*: versus nondiabetic controls adapted to [67]).